Hammelburg, Germany
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase
N/ASpan
337 weeksSponsor
Janssen Pharmaceutica N.V., BelgiumHamm
Recruiting
The "Global Paradise System" Registry
Phase
N/ASpan
520 weeksSponsor
ReCor Medical, Inc.Hamm
Recruiting
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics
Phase
3Span
408 weeksSponsor
University of UlmHamm
Recruiting
BAROSTIM THERAPY™ In Resistant Hypertension
Summary: The CVRx BAROSTIM THERAPY in Resistant Hypertension Registry will be performed with subjects who have been recently implanted with the BAROSTIM NEO System in accordance with CE-Mark approved criteria for resistant hypertension. Subjects must be enrolled within 30 days from implant. Up to 500 subjects will be enrolled at up to 50 sites. Data should be obtained from standard of care measurements taken prior to implant, at enrollment/baseline, and at 3, 6, and 12 months after the device was implanted. After 12 months, data may be obtained in six month intervals for up to three years after implant, at which time each subject will be exited from the registry. Eligibility: Subjects must sign an Ethics Committee (EC) approved informed consent form for the registry to participate. Subjects can be included in the Hypertension Registry if they were implanted in the past 30 days and meet the CE-Mark approved indications and contraindications for the BAROSTIM NEO System in the treatment of resistant hypertension. These include: - Indications - Systolic blood pressure greater than or equal to 140 mmHg, and - Resistance to maximally tolerated therapy with a diuretic and two other anti-hypertension medications - Contraindications - Bilateral carotid bifurcations located above the level of the mandible - Baroreflex failure or autonomic neuropathy - Uncontrolled, symptomatic cardiac bradyarrhythmias - Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% - Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation
Phase
N/ASpan
399 weeksSponsor
CVRx, Inc.Hamm
Recruiting
BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction
Summary: The CVRx BAROSTIM THERAPY in Heart Failure with Reduced Ejection Fraction (HFrEF) Registry will be performed with subjects who have been recently implanted with the BAROSTIM NEO System in accordance with CE-Mark approved criteria for heart failure. Subjects must be enrolled within 30 days from implant. Up to 500 subjects will be enrolled at up to 50 sites. Data should be obtained from standard of care measurements taken prior to implant, at enrollment/baseline, and at 3, 6, and 12 months after the device was implanted, at which time each subject will be exited from the registry. Eligibility: Subjects can be included in the Heart Failure with Reduced Ejection Fraction Registry if they were implanted in the past 30 days and meet the CE-Mark approved indications, and are not contraindicated, for the BAROSTIM NEO System in the treatment of heart failure. The BAROSTIM NEO System is indicated for subjects with heart failure, defined as New York Heart Association (NYHA) functional Class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy. The contraindications are: - Bilateral carotid bifurcations located above the level of the mandible - Baroreflex failure or autonomic neuropathy - Uncontrolled, symptomatic cardiac bradyarrhythmias - Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% - Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation Objectives: To describe change in the following measures at 3, 6 and 12 months compared to pre-implant baseline: - New York Heart Association (NYHA) Class - Six Minute Hall Walk - Echocardiogram measures - Biomarkers (e.g. NT-pro BNP, eGFR, Troponin HsT, Cystatin C). Evaluate health care utilization over follow-up, such as heart failure hospitalizations. Describe device programming and utilization
Phase
N/ASpan
399 weeksSponsor
CVRx, Inc.Hamm
Recruiting
Therapy Optimisation for the Treatment of Hairy Cell Leukemia
Evaluation of remission status will take place 4 months after treatment. In addition, it will be tested whether patients with non-optimal response will have a benefit from a second cycle of cladribine. Non-optimal response is: patients with detectable residual disease; achievement of partial remission or detectable residual infiltration in the bone marrow.
Phase
2/3Span
1235 weeksSponsor
University of GiessenHamm
Recruiting
Hamm
Recruiting
Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Phase
N/ASpan
1800 weeksSponsor
University of UlmHamm
Recruiting
Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)
Phase
N/ASpan
929 weeksSponsor
Bristol-Myers SquibbHamm
Recruiting
Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
Phase
N/ASpan
254 weeksSponsor
AbbVieHamm
Recruiting